<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113448</url>
  </required_header>
  <id_info>
    <org_study_id>MTU-EC-IM-5-195/59</org_study_id>
    <secondary_id>TCTR20170407001</secondary_id>
    <nct_id>NCT03113448</nct_id>
  </id_info>
  <brief_title>0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy</brief_title>
  <official_title>0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy: A Randomized, Double- Blind, Crossover, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thammasat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thammasat University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study that 0.075% capsaicin lotion is safe, well tolerated and provide significant pain
      relief in patients with PDN compared with placebo lotion as a randomized, double- Blind,
      crossover, placebo-controlled trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuropathy is one of the most common complications in both type 1 and type 2 diabetes
      mellitus. The most common symptom is a symmetrical, chronic, axonal, length-dependent
      sensorimotor polyneuropathy.

      Topical capsaicin formulations are widely used to manage pain. Low-concentration creams,
      lotions, and patches intended for daily skin application have been available in most
      countries since the early 1980s.

      We study 0.075% capsaicin lotion is safe, well tolerated and provide significant pain relief
      in patients with PDN compared with placebo lotion as a randomized, double- Blind, crossover,
      placebo-controlled trial for 20 weeks throughout the study in 42 participants. All
      participants are provided both 0.075% capsaicin lotion and placebo lotion. Each agent will be
      applied for 8 weeks then stop for 4 weeks, after that another agent will be used for 8 weeks.
      We keep following up all of them by calling and appointment to get information in
      effectiveness and adverse effect at 0,2,4,8,12,14,16,20 week, respectively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2017</start_date>
  <completion_date type="Anticipated">June 15, 2017</completion_date>
  <primary_completion_date type="Anticipated">April 21, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial, double blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale (0-100 mm.)</measure>
    <time_frame>20 week</time_frame>
    <description>scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short-form McGill Pain Questionnaire(SF-MPQ)</measure>
    <time_frame>20 week</time_frame>
    <description>scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Scale (NPS)</measure>
    <time_frame>20 week</time_frame>
    <description>scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Peripheral Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>0.075% Capsaicin Lotion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Lotion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.075% Capsaicin Lotion</intervention_name>
    <description>To apply 3-4 times per day, every day until 8 weeks then stop</description>
    <arm_group_label>0.075% Capsaicin Lotion</arm_group_label>
    <arm_group_label>Placebo Lotion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>To apply 3-4 times per day, every day until 8 weeks then stop</description>
    <arm_group_label>0.075% Capsaicin Lotion</arm_group_label>
    <arm_group_label>Placebo Lotion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. DM type 2 over 1 year

          2. Clinical presentation of peripheral sensory such as burning pain

          3. DN4 score from 4 points

          4. Good consciousness to tell their score with informed consent agreement

          5. No adding dosage of previous pain control medications at least 4 weeks

          6. HbA1C 6.5-9.0%

        Exclusion Criteria:

          1. Improper application site of skin for topical drugs such as abrasion wound.

          2. Allergic history of Capsaicin

          3. No intention to join the study with any reasons

          4. Other previous medications used that effect to peripheral neuropathy such as
             Carboplatin, Cisplatin, Colchicine, Dapsone, Etoposide, Ethambutol, Indomethacin,
             Isoniazid, Lithium, Metronidazole, Phenytoin, Pyridoxine, Statins, Stavudine (d4T) or
             conditions worsening peripheral nerves following that poor nutrition, kidney failure,
             chronic alcoholism, vitamin deficiency, Hypothyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kongkiat Kulkantrakorn, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Thammasat University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pasiri Sithinamsuwan</last_name>
    <role>Study Director</role>
    <affiliation>Phramongkutklao College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Assawin Chomjit</last_name>
    <phone>+66-874949239</phone>
    <email>cescassawin@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thammasat University Hospital</name>
      <address>
        <city>Pathumthani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Assawin Chomjit</last_name>
      <phone>+66-87-4949239</phone>
      <email>cescassawin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Assawin Chomjit</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kongkiat Kulkantrakorn</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thipaporn Tharavanij</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pasiri Sithinamsuwan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pitvara Panpitpat</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thammasat University</investigator_affiliation>
    <investigator_full_name>Assawin Chomjit</investigator_full_name>
    <investigator_title>Director, Clinical research</investigator_title>
  </responsible_party>
  <keyword>capsaicin</keyword>
  <keyword>neuropathic pain</keyword>
  <keyword>diabetic neuropathy</keyword>
  <keyword>topical lotion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

